Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb Company and Vanderbilt University have collaborated to discover, develop and commercialize novel therapies acting on the mGluR4 glutamate receptor (positive allosteric modulators or PAMs) to treat Parkinson's disease.
Subscribe to our email newsletter
Pursuant to the agreement, the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) will focus on identifying drug candidates from a program already receiving support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Bristol-Myers has rights to develop and commercialize the products resulting from the collaborative research program.
VCNDD medicinal chemistry director Craig Lindsley said, "We all look forward to a productive collaboration with Bristol-Myers Squibb, which brings tremendous expertise and a strong commitment to advancing the program."
Under the agreement, Vanderbilt University will earn upfront payment and multi-year research funding to continue to discover additional compounds and is entitled to receive milestones and royalties based on developmental success and worldwide sales of the drugs resulting from the collaboration.
Bristol-Myers research senior vice president Francis Cuss said, "We are thrilled to have the opportunity to work with the Vanderbilt Center for Neuroscience Drug Discovery’s highly regarded scientists and laboratories to potentially find a way to help patients with Parkinson’s disease."